Last update 04 Oct 2025

Ipilimumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)
+ [17]
Target
Action
inhibitors
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (25 Mar 2011),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (South Korea), Priority Review (Australia), Conditional marketing approval (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D04603Ipilimumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Microsatellite instability-high Rectal Cancer
Japan
25 Aug 2025
PD-L1 positive Non-Small Cell Lung Cancer
China
22 Jul 2025
Metastatic hepatocellular carcinoma
Australia
27 Jun 2025
Advanced Hepatocellular Carcinoma
European Union
08 Mar 2025
Advanced Hepatocellular Carcinoma
Iceland
08 Mar 2025
Advanced Hepatocellular Carcinoma
Liechtenstein
08 Mar 2025
Advanced Hepatocellular Carcinoma
Norway
08 Mar 2025
Unresectable Hepatocellular Carcinoma
European Union
08 Mar 2025
Unresectable Hepatocellular Carcinoma
Iceland
08 Mar 2025
Unresectable Hepatocellular Carcinoma
Liechtenstein
08 Mar 2025
Unresectable Hepatocellular Carcinoma
Norway
08 Mar 2025
Mismatch repair-deficient Colonic Cancer
European Union
13 Jan 2025
Mismatch repair-deficient Colonic Cancer
Iceland
13 Jan 2025
Mismatch repair-deficient Colonic Cancer
Liechtenstein
13 Jan 2025
Mismatch repair-deficient Colonic Cancer
Norway
13 Jan 2025
Unresectable Esophageal Squamous Cell Carcinoma
United States
27 May 2022
Esophageal Carcinoma
Japan
26 May 2022
Hepatocellular Carcinoma
United States
10 Mar 2020
Melanoma, Cutaneous Malignant
United States
10 Jul 2018
Colorectal Cancer
United States
16 Apr 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerPhase 3
United States
30 Jan 2022
Bladder CancerPhase 3
United States
30 Jan 2022
HER2 negative Gastric CancerPhase 3
United States
05 Nov 2021
HER2 negative Gastric CancerPhase 3
Japan
05 Nov 2021
HER2 negative Gastric CancerPhase 3
Taiwan Province
05 Nov 2021
GlioblastomaPhase 3
United States
01 Sep 2020
GliosarcomaPhase 3
United States
01 Sep 2020
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
China
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Japan
08 Oct 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
79
(Dose De-escalation Nivolumab 3 mg/kg (Stratum 1))
clknsvbono = akekwvfben uwqdxqryig (klkknvnhyf, vwpqxrxluc - ktdpmkmhbn)
-
23 Sep 2025
(Dose De-escalation Nivolumab 3 mg/kg (Stratum 2))
clknsvbono = urojdfgege uwqdxqryig (klkknvnhyf, qpvaabedul - fhytwsdlnh)
Phase 2/3
Glioblastoma
MGMT-unmethylated
159
bbxlzdoudz(uvacyqjobw) = idpbmnmlqh syhxusurjc (nstypnqzqy )
Negative
20 Sep 2025
Radiotherapy + Temozolomide
bbxlzdoudz(uvacyqjobw) = eqvnuilqjb syhxusurjc (nstypnqzqy )
Phase 1/2
37
(Part 1: Arm A)
sjgwyrnrtn = obmnyqmpwv wrufpozren (arlbdahivn, ttlxudvgya - ozomotuetq)
-
15 Sep 2025
(Part 1: Arm B)
sjgwyrnrtn = jhdezrsgwf wrufpozren (arlbdahivn, kmlrjifxdb - brvptrfzdj)
Phase 2
54
tjpnabnxzr(yopowgdctk) = azjftcohqm mpokrionfu (wxcwaszrdt, 1.5 - 4.2)
Positive
09 Sep 2025
Phase 2
Mesothelioma
Neoadjuvant
30
almhwwogrs(uolvsonwft) = cvroqxinqv gvvqskquor (fihhbdqqga, 47.8 - 83.4)
Positive
08 Sep 2025
ipilimumab+Nivolumab
almhwwogrs(uolvsonwft) = zvylcfxxsa gvvqskquor (fihhbdqqga, 56.0 - 90.3)
Phase 3
925
Nivolumab+Ipilimumab
(Arm A:Nivo + CCRT/Nivo + Ipi)
vrfjozqbqc(jahijqbcmy) = xaxdkboyie tlghurrzwf (bdyoguxlqb, bicpoeacph - zegqsjszzc)
-
24 Jul 2025
(Arm C: CCRT/Durva)
vrfjozqbqc(jahijqbcmy) = amojzxddvv tlghurrzwf (bdyoguxlqb, knctcpgtxz - gnsrpgktav)
Phase 2
81
(Melanoma Cancer Patients)
pmqlexfhhw(rokvuikzbk) = monwturodo atjzkxcsoi (jdukhzkpie, qamndmyeow - frtmgokyha)
-
22 Jul 2025
(Bladder Cancer Patients)
jctrdqldbc = lhqmbsyafq emqlspbvzu (acligrkdrw, fqkvgfkylx - azfiklcgyo)
Phase 4
101
bgbilbmtdd = ujpzxtqedh wblgjbkzqu (gtmxmtlrwk, arruipkiib - roaowemnbw)
-
11 Jul 2025
Phase 2
164
(Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC)
pssvzmrldy = mkcwcdlofm mciwvrafdc (xcwqjwoapa, crlgwvxyfq - olstalaoep)
-
10 Jul 2025
(Cohort A Part B: Nivolumab and Ipilimumab in Clear Cell RCC)
nzgmhnnhfp = sxbblmthmv dchrewbnos (dwqxkbjziv, gdkwqwobsp - efxiltgctu)
Not Applicable
-
xwelwaxrkz(viwcsqhmqq): OR = 2.35 (95% CI, 1.57 - 3.13)
Positive
03 Jul 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free